|Bid||52.43 x 3100|
|Ask||54.99 x 800|
|Day's Range||54.21 - 54.73|
|52 Week Range||40.81 - 54.73|
|Beta (5Y Monthly)||0.77|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jan 28, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||55.70|
Hologic (HOLX) expects to generate robust Surgical and Diagnostics revenues in Q1, though softness in the divested Medical Aesthetics business remains a concern.
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
It has been a fantastic year for equity investors as Donald Trump pressured Federal Reserve to reduce interest rates and finalized the first leg of a trade deal with China. If you were a passive index fund investor, you had seen gains of 31% in your equity portfolio in 2019. However, if you were an […]
Hologic to Announce Financial Results for the First Quarter of Fiscal 2020 on Wednesday, January 29, 2020
Hologic (HOLX) expects to witness favorable outcomes from the sell-off of the Cynosure medical aesthetics business, which was its loss-making arm since 2017.
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 13 at 8 a.m. Pacific Time.
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
Hologic, Inc. (HOLX) will showcase its comprehensive portfolio of breast and skeletal health products, including screening, interventional, surgical, ultrasound and skeletal solutions, in Booth #2511 at the 105th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) at McCormick Place in Chicago from Dec. 1 to 5. The world leader in mammography, Hologic continues to expand and strengthen its preeminent position in breast health, most recently ranking first in customer satisfaction, service and system performance on the 2019 IMV ServiceTrack™ Diagnostic Imaging report, an annual customer satisfaction survey on the medical imaging industry. Among mammography categories overall, Hologic tops the list for the fourth consecutive year, a testament to the Company’s ongoing dedication to insight-driven innovation, diagnostic leadership, product quality and service in women’s healthcare.
Clinical evidence demonstrating the effectiveness of new FDA-cleared assays for the detection of vaginitis has been published online in the Journal of Clinical Microbiology. The prospective, multi-center clinical study is the first in the United States to formally validate the performance of the Aptima® BV and Aptima® CV/TV assays, available from Hologic, Inc. (Nasdaq: HOLX) on its fully automated Panther® system.
Hologic Inc. said Wednesday it has agreed to sell its Cynosure medical aesthetics business to funds managed by private-equity firm Clayton, Dubilier & Rice for $205 million in cash. The company, which focuses on health care for women, expects to receive net proceeds following closing adjustments of about $138 million. Hologic Chief executive Steve MacMillan said Cynosure, which was acquired in 2017, has "significantly underperformed" expectations. The company will transfer about 825 employees with the change in ownership. The deal is expected to close around year-end. The company expects to book a "significant" non-cash impairment charge in the fourth quarter and an additional $155 million to $185 million pre-tax impairment charge to reduce the carrying value of the asset group to its fair value. "In the first quarter of fiscal 2020, this asset group will meet the criteria for assets held-for sale and will be recorded at fair value less costs to sell, which could result in additional charges," it said in a statement. Hologic is also planning an accelerated share buyback of $205 million. The buyback and sale are expected to raise EPS by about 2 cents in fiscal 2020, while the loss will create a tax refund of at least $300 million that will be received in 2022. Shares rose 1.8% in premarket trade and have gained 14.7% in 2019, while the S&P 500 has gained 24.5%.
Hologic, Inc. (HOLX) announced today that it has entered into a definitive agreement to sell its Cynosure medical aesthetics business to an affiliate of investment funds managed by Clayton, Dubilier & Rice for a total purchase price of $205 million in cash, subject to certain closing adjustments. Net of these adjustments, Hologic expects net cash proceeds of approximately $138 million. "Divesting our medical aesthetics business will enable us to focus on what we do best – helping women and their families live healthier lives through early detection of disease," said Steve MacMillan, the Company's Chairman, President and Chief Executive Officer.
Carveout Transaction Positions Cynosure for Accelerated Growth Under New Ownership NEW YORK , Nov. 20, 2019 /PRNewswire/ -- Clayton, Dubilier & Rice today announced an agreement under which CD&R-managed ...